Literature DB >> 19445944

Time trends in therapies and outcomes for adult inflammatory bowel disease, Northern California, 1998-2005.

Lisa J Herrinton1, Liyan Liu, Bruce Fireman, James D Lewis, James E Allison, Nicole Flowers, Susan Hutfless, Fernando S Velayos, Oren Abramson, Andrea Altschuler, Geraldine S Perry.   

Abstract

BACKGROUND & AIMS: The management of inflammatory bowel disease (IBD) has become increasingly complicated, and it is unknown whether poor outcomes (prolonged steroid use, hospitalizations, and surgery) have declined in the general population.
METHODS: This multilevel study used computerized clinical data. The study comprised 2892 adults with Crohn's disease (CD) and 5895 with ulcerative colitis (UC) who received care at 16 medical centers within an integrated care organization in Northern California between 1998 and 2005.
RESULTS: Time trends included (1) a shift in gastroenterology-related visits from the gastroenterology division to primary care; (2) increased use of IBD-related drugs, except for a 7% decline in use of 5-aminosalicylate in CD and no change in steroid use for CD; (3) for the prevalence of prolonged steroid exposure (120 days of continuous use), a 36% decline for CD with a 27% increase for UC; (4) declines in the hospitalization rates of 33% for CD and 29% for UC; and (5) for the surgery rate, no significant change for CD with a 50% decline for UC.
CONCLUSIONS: Declines in prolonged steroid exposure and the hospitalization rate for CD and in the hospitalization and surgery rate for UC are encouraging; however, the increase in prolonged steroid exposure for UC merits concern and further investigation. The variability in care patterns observed in this study suggests lack of standardization of care and the opportunity to identify targets for quality improvement. These findings should stimulate research to quantify the effect of current trends in IBD management.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19445944     DOI: 10.1053/j.gastro.2009.04.063

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  32 in total

1.  Association between maternal inflammatory bowel disease and adverse perinatal outcomes.

Authors:  D Getahun; M J Fassett; G F Longstreth; C Koebnick; A M Langer-Gould; D Strickland; S J Jacobsen
Journal:  J Perinatol       Date:  2014-03-20       Impact factor: 2.521

2.  Risk of diagnosed fractures in children with inflammatory bowel diseases.

Authors:  Michael D Kappelman; Joseph A Galanko; Carol Q Porter; Robert S Sandler
Journal:  Inflamm Bowel Dis       Date:  2010-09-24       Impact factor: 5.325

Review 3.  Quality of care delivered to hospitalized inflammatory bowel disease patients.

Authors:  Adam V Weizman; Geoffrey C Nguyen
Journal:  World J Gastroenterol       Date:  2013-10-14       Impact factor: 5.742

4.  Immunosuppressed Patients with Crohn's Disease Are at Increased Risk of Postoperative Complications: Results from the ACS-NSQIP Database.

Authors:  Maria Abou Khalil; Jad Abou-Khalil; Jennifer Motter; Carol-Ann Vasilevsky; Nancy Morin; Gabriela Ghitulescu; Marylise Boutros
Journal:  J Gastrointest Surg       Date:  2019-03-18       Impact factor: 3.452

5.  The impact of Hispanic ethnicity and race on post-surgical complications in patients with inflammatory bowel disease.

Authors:  Andres J Yarur; Maria T Abreu; Mark S Salem; Amar R Deshpande; Daniel A Sussman
Journal:  Dig Dis Sci       Date:  2013-03-13       Impact factor: 3.199

6.  Crohn's disease and ulcerative colitis are associated with elevated standardized mortality ratios: a meta-analysis.

Authors:  Meenakshi Bewtra; Lisa M Kaiser; Tom TenHave; James D Lewis
Journal:  Inflamm Bowel Dis       Date:  2013-03       Impact factor: 5.325

Review 7.  Has the risk of colorectal cancer in inflammatory bowel disease decreased?

Authors:  Nynne Nyboe Andersen; Tine Jess
Journal:  World J Gastroenterol       Date:  2013-11-21       Impact factor: 5.742

Review 8.  Challenges in designing a national surveillance program for inflammatory bowel disease in the United States.

Authors:  Millie D Long; Susan Hutfless; Michael D Kappelman; Hamed Khalili; Gilaad G Kaplan; Charles N Bernstein; Jean Frederic Colombel; Corinne Gower-Rousseau; Lisa Herrinton; Fernando Velayos; Edward V Loftus; Geoffrey C Nguyen; Ashwin N Ananthakrishnan; Amnon Sonnenberg; Andrew Chan; Robert S Sandler; Ashish Atreja; Samir A Shah; Kenneth J Rothman; Neal S Leleiko; Renee Bright; Paolo Boffetta; Kelly D Myers; Bruce E Sands
Journal:  Inflamm Bowel Dis       Date:  2014-02       Impact factor: 5.325

Review 9.  Blood transfusion for the treatment of acute anaemia in inflammatory bowel disease and other digestive diseases.

Authors:  José Antonio García-Erce; Fernando Gomollón; Manuel Muñoz
Journal:  World J Gastroenterol       Date:  2009-10-07       Impact factor: 5.742

10.  Race and inflammatory bowel disease in an urban healthcare system.

Authors:  Justin L Sewell; John M Inadomi; Hal F Yee
Journal:  Dig Dis Sci       Date:  2010-10-09       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.